Clinical trial · Interventional
Feasibility And Efficacy Of An iPad-Based Cognitive Rehabilitation Program In Brain Tumor Patients
NCT02783495CI-TRIAL-00042798terminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Funding
Summary
Brief summary (as posted)
This pilot clinical trial studies how well an iPad-based cognitive rehabilitation program works in improving quality of life in patients with grade II-III glioma. An iPad-based cognitive rehabilitation program may help to increase patients cognitive function and quality of life, and may provide doctors with valuable information for optimizing care of patients with brain tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Device: iPad | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Device: iPad
- description
- Patients with brain tumors receive an iPad with the ReMind app. The patients will use the app to train neurocognitive and compensatory skills for 3 hours per week over the course of 12 weeks (36 hours in total)
- interventionNames
- Behavioral: Device: iPad
Primary outcomes (6)
- measure
- Number of subjects who complete the intervention
- timeFrame
- At 3 months after start of training
- description
- Subjects who complete all of the intervention exercises (approximately 36 hours of intervention).
- measure
- Patient-reported ease of use
- timeFrame
- At 3 months after start of training
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must have histologically confirmed WHO grade 2 or 3 gliomas. * Patients must be \> 18 years old * Patients must have a life expectancy \> 12 weeks. * Patients must have a Karnofsky performance status of \> 70. * This study was designed to include women and minorities, but was not designed to measure differences between them. Males and females will be recruited with no preference to gender. Minorities will actively be recruited to participate. No exclusion to this study will be based on race. * Patients must speak and be able to read English fluently. * All patients must sign an informed consent indicating that they are aware of the investigational nature of this study. Patients must sign an authorization for the release of their protected health information. * Patients may not be known to be HIV-positive. HIV testing is not required for study participation. * Patients must not have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off of all therapy for that disease for a minimum of 3 years. * Patients must be receiving MRI scans at UCSF * Patients must be clinically stable and off treatment (e.g. radiation or chemotherapy) for ≥ 6 months * Patients must be ≥ 6 months from craniotomy * Patients must have subjective complaints of cognitive deficits. * Patients must have adequate seizure control and be on a stable, or decreasing, dose of anti-epileptics Exclusion Criteria: * Patients who are not able to comply with study and/or follow-up procedures. * Patients who do not have home access to the Internet. * Patients who, based on the physician's opinion, are unable to participate in neurocognitive testing and/or neurocognitive rehab secondary to significant neurologic deficit
References
Publications (0)
Data not yet available
No reference posted for this study.